~~<i id='2D623AB738'><strike id='2D623AB738'><tt id='2D623AB738'><pre id='2D623AB738'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

comprehensive

author：leisure time 2025-09-30 12:57:04 - browse：25

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Eli Lilly to pay $200M for Beam’s stake in gene

leisure time

focus

hotspot

entertainment

hotspot

KristofferTripplaar/SipaviaAPImagesSanofi,theParis-baseddruggiant,announcedFridaythatitwouldspinouti

WSS

Testing for cancer recurrence creates a new limbo for patients

Senate panel to vote on hospitals, PBMs, prisoner care

FDA drug safety: Singulair case shows systemic surveillance flaws

Traditional Chinese medicine benefits explored in new JAMA study

Cassava reveals details — and problems — with Alzheimer's study

Readout Newsletter: XBI biotech index, Akero Therapeutics

leisure time

comprehensive

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

The real point of Kenneth Smith’s execution by nitrogen gas

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Sports medicine is finally prioritizing gender equality

Eli Lilly to pay $200M for Beam’s stake in gene

Peter Hotez and the public health issue of online harassment

Medicare drug price negotiation’s day in court

Walensky prepares to leave CDC — and Congress — behind

Hospitals warn Medicare's drug payment fix is ‘unlawful’

focus

Maker of FluMist seeks to allow at

Chimpanzees, like humans and whales, get menopause: Study

Readout Newsletter: New research from Sanofi, Regeneron, etc.

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Emergency medicine has repudiated 'excited delirium.' Now what?

The real point of Kenneth Smith’s execution by nitrogen gas

hotspot

hotspot

entertainment

hotspot